본문 바로가기
  • Home

A Randomized Trial Comparing the Effect of Unani Formulation with Metronidazole in Bacterial Vaginosis

  • CELLMED
  • Abbr : CellMed
  • 2023, 13(14), pp.5-5
  • DOI : 10.5667/CellMed.2023.018
  • Publisher : Cellmed Orthocellular Medicine and Pharmaceutical Association
  • Research Area : Medicine and Pharmacy > General Medicine
  • Received : September 26, 2023
  • Accepted : November 22, 2023
  • Published : November 30, 2023

Nazia Usmoni 1 Mariyam Roqaiya 2 Mohd Aqil Quadri 3 Arshiya Sultana 3 Taseen Banu 4 Sumbul Alam 2

1Department of Niswan wa Qabalat, Luqman Unani, Medical College, Hospital and Research Centre
2Department of Niswan wa Qabalat, State Takmeel-ut-Tib College
3Department of Niswan wa Qabalat, National Institute of Unani Medicine
4GPHC

Accredited

ABSTRACT

Background and objectives: Bacterial vaginosis (BV) is recognized as the most prevalent type of vaginal infection, impacting approximately 19-24% of women in their reproductive years. The recurrence rate of BV is significant, negatively impacting the well-being of affected women. This study aimed to compare the therapeutic effects of a polyherbal Unani formulation and metronidazole in treating bacterial vaginosis. Methodology: In this prospective patient blinded standard controlled trial, a total of 40 individuals with a clinical diagnosis of bacterial vaginosis were randomly assigned to receive either an active control treatment (n = 20) or a test drug (n = 20). In the test drug combination of Acacia catechu, Azadirachta indica and Quercus infectoria in tablet (1g) form in the dose of 2 tablets orally twice daily with water was administered for 3 weeks. In the active control standard drug, metronidazole 400 mg tablet, orally twice daily was given for one week. The primary outcome measure was clinical cure; H. negative Amsel’s criteria and a reduction in subjective symptoms, while the secondary outcome measure was an improvement in SF-36 quality of life (QOL). Results and conclusion: Both the experimental treatment and the metronidazole demonstrated a significant clinical cure for bacterial vaginosis as well as an increase in health-related quality of life. Based on these findings, it appears that the test medication is a potent Unani formulation for the treatment of bacterial vaginosis. A well conducted trial with a bigger sample size is required to corroborate these findings.

Citation status

* References for papers published after 2023 are currently being built.